|
Ted W. Love, M.D. was appointed president and chief executive officer of Nuvelo, Inc. in March 2001, having been appointed president and chief operating officer of the company in January 2001. He has served as a director of the company since February 2001 and became chairman of the board in September 2005. Dr. Love joined Nuvelo from Theravance Inc., where he served as senior vice president of development from February 1998 to January 2001. Previously, Dr. Love spent six years at Genentech Inc., holding a number of senior management positions in Medical Affairs and Product Development. As vice president of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech's Product Development Committee. Dr. Love earned his bachelor's degree in molecular biology from Haverford College and his medical degree at Yale Medical School. He completed his residency and fellowship training in internal medicine and cardiology at Massachusetts General Hospital and Harvard Medical School. Following residency training, Dr. Love joined the faculty of Massachusetts General in the department of cardiology. He also serves as a member of the boards of directors of Affymax, Inc., Predix Pharmaceuticals, Inc., Santarus, Inc. and the California Healthcare Institute and serves on the 29-member California Independent Citizens' Oversight Committee (ICOC), which oversees the $3 billion allocated to stem cell research authorized by Proposition 71.
| 